Center for Drug Discovery, 116 Mugar Life Sciences Building, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, United States.
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5999-6002. doi: 10.1016/j.bmcl.2011.07.017. Epub 2011 Jul 23.
To obtain information on the pharmacophoric requirements of the CB1/CB2 partial agonist BAY 59-3074 we have synthesized a series of new conformationally constrained dibenzofuran (4a-d) and dibenzopyran analogs (5). All constrained analogs exhibited reduced binding affinity at both cannabinoid receptor subtypes, suggesting that planar conformations of these ligands are less favored by both receptors. We also found that 4c, 4d, and 5 exhibited 3- to 12-fold selectivity for hCB2 over rCB1 receptors and may serve as new chemotypes for the development of CB2-selective cannabinergics.
为了获取 CB1/CB2 部分激动剂 BAY 59-3074 的药效团需求信息,我们合成了一系列新的刚性二苯并呋喃(4a-d)和二苯并吡喃类似物(5)。所有的刚性类似物在两种大麻素受体亚型上的结合亲和力都降低了,这表明这些配体的平面构象对两种受体的亲和力都较低。我们还发现 4c、4d 和 5 对 hCB2 受体相对于 rCB1 受体具有 3 至 12 倍的选择性,它们可能成为开发 CB2 选择性大麻素受体激动剂的新型化学型。